A Phase I Study to Assess the Safety, Tolerability, and Pharmacokinetics of XH-S002 After Single Ascending Doses, Multiple Ascending Doses and Evaluation of Food Effects in Healthy Volunteers
Latest Information Update: 16 Jan 2024
At a glance
- Drugs XH S002 (Primary)
- Indications Unspecified
- Focus Adverse reactions
- Sponsors S-Infinity Pharmaceuticals
- 16 Jan 2024 New trial record